VVUS - VIVUS, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.4783
+0.0033 (+0.6947%)
At close: 4:00PM EST

0.4800 0.00 (0.36%)
After hours: 4:36PM EST

Stock chart is not supported by your current browser
Previous Close0.4750
Open0.4800
Bid0.4750 x 14500
Ask0.5000 x 10000
Day's Range0.4750 - 0.4993
52 Week Range0.4500 - 1.3800
Volume370,234
Avg. Volume703,070
Market Cap50.677M
Beta0.45
PE Ratio (TTM)1.41
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cubelast month

    ETFs with exposure to VIVUS, Inc. : December 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to VIVUS, Inc. : December 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to VIVUS, Inc. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMT

    Q3 2017 VIVUS Inc Earnings Call

  • Capital Cube2 months ago

    ETFs with exposure to VIVUS, Inc. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
    Zacks2 months ago

    VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

    VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

  • VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cube2 months ago

    VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis VIVUS, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of VIVUS, Inc. – Apricus Biosciences, Inc., Pfizer Inc., Cardinal Health, Inc., Eli Lilly and Company, AmerisourceBergen Corporation and Arena Pharmaceuticals, Inc. (APRI-US, PFE-US, CAH-US, LLY-US, ABC-US and ARNA-US) that ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to VIVUS, Inc. : October 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
    Capital Cube4 months ago

    VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017

    Categories: Yahoo FinanceGet free summary analysis VIVUS, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 11.23 million, Net Earnings of USD -13.39 million. Gross margins narrowed from 80.79% to 68.20% compared to the same period last year, operating (EBITDA) margins now -42.20% from -24.58%. Change in operating cash ... Read more (Read more...)

  • Orexigen's (OREX) Contrave Sales Improving on Promotions
    Zacks4 months ago

    Orexigen's (OREX) Contrave Sales Improving on Promotions

    Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.

  • VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug
    Zacks5 months ago

    VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug

    VIVUS, Inc. (VVUS) signed an agreement with Alvogen giving rights to the latter to market anti-obesity drug Qsymia in Korea for the treatment of chronic weight management or weight-related conditions.

  • VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?
    Zacks5 months ago

    VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?

    VIVUS (VVUS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
    Zacks6 months ago

    VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y

    VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.

  • VIVUS Settles with Teva on Weight Management Drug Generic
    Zacks7 months ago

    VIVUS Settles with Teva on Weight Management Drug Generic

    VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.

  • BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase
    Zacks7 months ago

    BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase

    BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).

  • Roche (RHHBY) Launches Cobas Test for Bacterial Infections
    Zacks7 months ago

    Roche (RHHBY) Launches Cobas Test for Bacterial Infections

    Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.

  • Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label
    Zacks7 months ago

    Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label

    Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.

  • Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU
    Zacks7 months ago

    Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU

    Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.

  • Acorda Files NDA for Parkinson's Disease Candidate Inbrija
    Zacks7 months ago

    Acorda Files NDA for Parkinson's Disease Candidate Inbrija

    Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.

  • Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA
    Zacks7 months ago

    Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA

    Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu.

  • KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline
    Zacks7 months ago

    KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline

    KemPharm, Inc. (KMPH) announced that it has strengthened its attention deficit hyperactivity disorder (ADHD) produg pipeline portfolio.

  • Zacks7 months ago

    Neothetics' Fat Reduction Candidate Fails in Phase II Study

    Neothetics, Inc. (NEOT) announced disappointing top line results from a phase II proof-of-concept study, LIPO-202-CL-31, evaluating its lead candidate, LIPO-202, for reduction of submental subcutaneous fat.

  • Seattle Genetics (SGEN) Reports Positive Data for Adcetris
    Zacks7 months ago

    Seattle Genetics (SGEN) Reports Positive Data for Adcetris

    Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.

  • Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti
    Zacks7 months ago

    Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

    Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.

  • Shire (SHPG) Receives MAA Validation for Veyvondi by EMA
    Zacks7 months ago

    Shire (SHPG) Receives MAA Validation for Veyvondi by EMA

    Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.